Measuring TIMP-1 Levels in Blood for Cancer Diagnosis
Author Information
Author(s): Holten-Andersen M N, Murphy G, Nielsen H J, Pedersen A N, Christensen I J, Høyer-Hansen G, Brünner N, Stephens R W
Primary Institution: The Finsen Laboratory, Copenhagen University Hospital
Hypothesis
Can TIMP-1 levels in plasma serve as a diagnostic and prognostic marker for cancer patients?
Conclusion
The study found that TIMP-1 levels are significantly higher in patients with advanced cancer compared to healthy individuals.
Supporting Evidence
- TIMP-1 levels in healthy blood donors averaged 69.2 μg l−1.
- TIMP-1 levels in patients with Dukes' stage D colorectal cancer averaged 240 μg l−1.
- A significant difference in TIMP-1 levels was found between healthy donors and cancer patients.
Takeaway
This study shows that a blood test can measure a substance called TIMP-1, which is higher in people with serious cancer.
Methodology
A kinetic enzyme-linked immunosorbent assay (ELISA) was developed to measure TIMP-1 levels in plasma samples.
Participant Demographics
143 patients with Dukes' stage D colorectal cancer and 19 patients with advanced breast cancer.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website